AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

Manuscript Number: 

15-0834R1

Author(s): 
Robert C. Alexander, Anna Bogstedt, Gvido Cebers, Susanna Eketjäll, Johanna Fälting, Samantha Budd Haeberlein, Juliette Janson, Fredrik Jeppsson, Karin Kaspersson, Alan R. Kugler

Disclosures

Robert C. Alexander

  • Sponsors:
    Not currently but I was employed by AstraZeneca when the work was done.

Anna Bogstedt

  • Sponsors:
    AstraZeneca employee

Gvido Cebers

  • Equity:
    I own AstraZeneca stock in a mutual fund.
    Sponsors:
    I am employed by AstraZeneca Pharmaceuticals, have been since 2004.

Susanna Eketjäll

  • Equity:
    AstraZeneca
    Sponsors:
    AstraZeneca employee

Johanna Fälting

  • Nothing to Disclose

Samantha Budd Haeberlein

  • Nothing to Disclose

Juliette Janson

  • Equity:
    AstraZeneca
    Sponsors:
    AstraZeneca employee

Fredrik Jeppsson

  • Sponsors:
    AstraZeneca employee

Karin Kaspersson

  • Equity:
    AstraZeneca
    Sponsors:
    AstraZeneca employee

Alan R. Kugler

  • Equity:
    AstraZeneca
    Sponsors:
    AstraZeneca employee